Prospective Randomized Open Label Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or Low Molecular Weight Heparin in Pediatric Subjects with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: thromboprophylaxis | Heart disease
Age: Between 0 - 18 Years
Gender: Male or Female
Congenital or acquired heart diseases requiring chronic anticoagulation for thromboprophylaxis (eg, single ventricle physiology including all 3 stages of palliation, dilated cardiomyopathy, Kawasaki disease with coronary aneurysms, and pulmonary hypertension).
Eligible subjects include those who newly start anticoagulants and those who are currently on VKA or LMWH or other anticoagulants for thromboprophylaxis.
Able to tolerate enteral medication [eg, by mouth, Nasogastric (NG) tube, or Gastric-(G) tube].
Recent thromboembolic events less than 6 months prior to enrollment
Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment
Prosthetic heart valves, and mechanical heart valves
Active bleeding at the time of enrollment
Known inherited bleeding disorder or coagulopathy (eg, hemophilia, von Willebrand disease, etc)
Known intracranial congenital vascular malformation or tumor
Any major bleeding other than perioperative in the preceding 3 months
Uncontrolled severe hypertension
In the opinion of the Investigator, it is not possible for the subject to be compliant with the protocol and study procedures
Pregnancy during the study period
Concurrent use of or participation in another experimental drug/device trial
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required